Brind.

Commercial deals were signed for the Padcev-Keytruda combo regimen, challenging Opdivo market share, with NHS adoption pending FDA approval.

1 report, 1 independent Updated Aug 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Commercial deals were signed for the Padcev-Keytruda combo regimen, challenging Opdivo market share, with NHS adoption pending FDA approval.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Pharmaceutical TechnologyPadcev-Keytruda combo approved for NHS use in mUC The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new combination regimen in metastatic urothelial carcinoma (mUC)